These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 22730307

  • 1. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
    Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, Do HT, Mandl LA.
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
    [Abstract] [Full Text] [Related]

  • 2. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [Abstract] [Full Text] [Related]

  • 3. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
    Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P.
    Ann Oncol; 2013 Feb; 24(2):350-355. PubMed ID: 23038762
    [Abstract] [Full Text] [Related]

  • 4. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
    Shanmugam VK, McCloskey J, Elston B, Allison SJ, Eng-Wong J.
    Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
    [Abstract] [Full Text] [Related]

  • 5. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
    Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P.
    J Clin Oncol; 2008 Jul 01; 26(19):3147-52. PubMed ID: 18474874
    [Abstract] [Full Text] [Related]

  • 6. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V.
    Breast Cancer Res Treat; 2019 Aug 01; 176(3):617-624. PubMed ID: 31079282
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
    Singer O, Cigler T, Moore AB, Levine AB, Do HT, Mandl LA.
    Breast J; 2014 Aug 01; 20(2):174-9. PubMed ID: 24467395
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
    Henry NL, Jacobson JA, Banerjee M, Hayden J, Smerage JB, Van Poznak C, Storniolo AM, Stearns V, Hayes DF.
    Cancer; 2010 Sep 15; 116(18):4360-7. PubMed ID: 20549827
    [Abstract] [Full Text] [Related]

  • 13. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
    Martínez N, Herrera M, Frías L, Provencio M, Pérez-Carrión R, Díaz V, Morse M, Crespo MC.
    Clin Transl Oncol; 2019 Apr 15; 21(4):489-498. PubMed ID: 30293230
    [Abstract] [Full Text] [Related]

  • 14. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
    Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL, Meyskens FL, Moinpour CM.
    J Clin Oncol; 2015 Jun 10; 33(17):1910-7. PubMed ID: 25940724
    [Abstract] [Full Text] [Related]

  • 15. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
    Li H, Sereika SM, Marsland AL, Conley YP, Bender CM.
    J Clin Nurs; 2019 Dec 10; 28(23-24):4560-4571. PubMed ID: 31469461
    [Abstract] [Full Text] [Related]

  • 16. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, Tsai ML, Shapiro AC.
    Oncol Nurs Forum; 2013 Nov 10; 40(6):549-57. PubMed ID: 24161633
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
    Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E.
    Breast Cancer Res Treat; 2012 Jan 10; 131(1):277-85. PubMed ID: 21904883
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.